TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

NCT07223203 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
hATTR-PN

Interventions

DRUG: Nucresiran
DRUG: Vutrisiran

Sponsor

Alnylam Pharmaceuticals